Los Angeles Capital Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 121,000 shares of the biopharmaceutical company’s stock after purchasing an additional 17,716 shares during the period. Los Angeles Capital Management LLC owned 0.10% of Halozyme Therapeutics worth $4,922,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the stock. TD Asset Management Inc boosted its position in shares of Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after buying an additional 1,662,390 shares during the period. Norges Bank purchased a new position in Halozyme Therapeutics in the 4th quarter worth approximately $44,935,000. Epoch Investment Partners Inc. grew its position in Halozyme Therapeutics by 250.5% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after acquiring an additional 831,199 shares in the last quarter. Boston Partners raised its stake in shares of Halozyme Therapeutics by 562.2% during the fourth quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock valued at $20,218,000 after purchasing an additional 468,977 shares during the period. Finally, LSV Asset Management acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $17,090,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $45.38, for a total value of $453,800.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at $7,631,826.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 30,000 shares of company stock worth $1,338,800 over the last quarter. 2.40% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on HALO
Halozyme Therapeutics Price Performance
Shares of NASDAQ HALO opened at $50.86 on Friday. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The company has a market capitalization of $6.47 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 0.51 and a beta of 1.28. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $53.00. The business has a 50 day simple moving average of $43.67 and a 200-day simple moving average of $39.97.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.07. The firm had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Stock Splits, Do They Really Impact Investors?
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- Dividend Payout Ratio Calculator
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.